Therapie der Endometriose

Ludwig Kiesel, Kiesel L, L Kiesel, Bertges K, Karin Bertges, K Bertges, T. Rabe, T R von Holst, von Holst TR, Runnebaum B, Th. von Holst, B. Runnebaum
Archives of gynecology and obstetrics · 1989 · vol. 245(1-4) , pp. 937–940 · doi:10.1007/bf02417628 · PMID:2679444 · W2780816766
article OA: closed CC0 ⤵ 7 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-07 ⓘ

Gestrinone and danazol both effectively treated endometriosis with similar pregnancy rates but different side effects, while buserelin induced implant reduction with estrogenic suppression side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This paper reports randomized trial evidence comparing hormonal therapies for endometriosis, including a study of 30 laparoscopically confirmed patients treated for 6 months with gestrinone versus danazol, and a multinational multicenter trial of 275 patients treated with the GnRH agonist buserelin intranasally. Across studies, treatment was effective in roughly 80–90% of cases, with similar pregnancy rates for gestrinone versus danazol, while buserelin induced disappearance or reduction of endometriotic implants in about 80%; the main side effects were attributed to estrogen suppression and differed between drug groups. A key limitation explicitly highlighted is the ongoing need to determine recurrence rates and long-term side effects, implying follow-up beyond the reported treatment periods is central. This paper is centrally about endometriosis — it compares gestrinone, danazol, and buserelin hormonal regimens and reports response and side-effect profiles.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In a randomized study, the effect of gestrinone (2 x 2.5 mg/week) was compared with the effect of danazol (3 x 200 mg/day) in treating 30 patients with laparoscopically proven endometriotic implants for 6 months. Therapy was effective in 80%-90% of cases and pregnancy rates were similar, but the incidence of side effects was different in the groups. In addition, buserelin (900 micrograms/day intranasally) was investigated in a multinational, multicenter trial in 275 patients. In 80%, GnRH agonist treatment induced the disappearance or reduction of endometriotic implants. The main side effects were due to estrogenic suppression. Presently, various methods of hormonal treatment are under investigation, especially to determine recurrency rates of endometriosis and long-term side effects.
Full text 4,327 characters · extracted from oa-doi-fallback · click to expand
Summary In a randomized study, the effect of gestrinone (2×2,5 mg/week) was compared with the effect of danazol (3×100 mg/day) in treating 30 patients with laparoscopically proven endometriotic implants for 6 months. Therapy was effective in 80%–90% of cases and pregnancy rates were similar but the incidence of side effects was different in the groups. In addition, buserelin (900 μg/day intranasally) was investigated in a multinational, multicenter trial in 275 patients. In 80%, GnRH agonsit treatment induced the disappearance or reduction of endometriotic implants. The main side effects were due to estrogenic suppression. Presently, various methods of hormonal treatment, are under investigation, especially to determine recurrency rates of endometriosis and long-term side effects. Zusammenfassung In einer randomisierten Studie wurden bei 30 Patientinnen 6 Monate lang die Wirkungen von Gestrinon (2×2,5 mg/Woche) und Danazol (3×200 mg/Tag) verglichen. Bei erfolgreicher Therapie in 80–90% der Fälle und ähnlicher Schwangerschaftsrate traten in beiden Gruppen jedoch unterschiedliche Nebenwirkungen auf. Zusätzlich wurde, Buserelin in einer multinationalen multizentrischen Studie an 275 Patientinnen mit intranasalen Gaben von 900 μg/Tag untersucht. Bei 80% führte die Behandlung mit dem GnRH-Agonisten zum Abheilen oder zum Rückgang der Implantate Die hauptsächlichen Nebenwirkungen waren auf die Östrogensuppression zurückzuführen. Zur Zeit werden verschiedene Methoden im Hinblick auf Rezidivraten und Langzeit-Nebenwirkungen getestet. Similar content being viewed by others Literatur Cirkel U, Schweppe KW, Ochs H, Schneider HPG (1987) Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriosebehandlung mit einem LHRH-Agonisten. Geburtsh Frauenheilk 47: 154–157 Cornillie FJ, Vasquez G, Brosens I (1985) The response of human endometriotic implants to the anti-progesterone steroid R 2323: a histologic and ultrastructural study. Path Res Pract 180: 647–655 Dlugi AM, Rufo S, D'Amico JF, Seibel MM (1988) A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 49: 913–916 Donnez J, Lemaire-Rubbers M, Karaman Y, Nisolle-Pochet M, Casanas-Roux F (1987) Combined (hormonal and microsurgical) therapy in infertile women with endometriosis. Fertil Steril 48: 239–242 Hardt W, Schmidt-Gollwitzer M, Schmidt-Gollwitzer K, Genz T, Nevinny-Stickel J (1986) Initial results in the treatment of endometriosis with the LHRH analogue buserelin. Geburtsh Frauenheilk 46: 483 Henzl MR, Corson SL, Moghissi K, Buttram VC, Berquist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 318: 485–489 Kiesel L, Bertges K, Rabe T, Runnebaum B (1986) Gonadotropin releasing hormone enhances polyphosphoinositide hydrolyis, in rat pituitary cells. Biochem Biophys Res Commun 134: 861 Kiesel L, Catt KJ (1987) Stimulation of luteinizing hormone release and cyclic nucleotide production by arachidonic acid in cultured gonadotrophs. Neuroendocrinology 46: 1 Kiesel L, Kaufmann M, Haeseler F, Klinga K, von Holst T, Schmidt W, Runnebaum B (1988) GnRH receptors in human breast cancer tissue. Geburtsh Frauenheilk 48: 420–424 Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by luteinizing hormone releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41: 863 Mettler L (1987) Vergleich der medikamentösen Behandlung der Endometriosis genitalis externa mit Gestrinon, Lynestrenol und Danazol im Rahmen der Drei-Stufen-Behandlung. Fertilität 3: 133–139 Schneider HPG, Schweppe K-W, Cirkel U, Ochs H (1986) Management of endometriosis. In: Rolland R, Chadha DR, Willemsen WNP (eds) Gonadotropin Down-Regulation in Gynecological Practice. Progr Clin Biol Res vol 225. Alan R Liss, New York, pp 135–156 Schweppe K-W (1984) Morphologie und Klinik der Endometriose. Schattauer, Stuttgart New York Author information Authors and Affiliations Rights and permissions About this article Cite this article Kiesel, L., Bertges, K., Rabe, T. et al. Therapie der Endometriose. Arch Gynecol Obstet 245, 937–940 (1989). https://doi.org/10.1007/BF02417628 Issue date: DOI: https://doi.org/10.1007/BF02417628

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Gestrinone Norpregnatrienes Pregnadienes Uterine Neoplasms Adult Danazol Endometriosis Female Gestrinone Humans Norpregnatrienes Pregnadienes Randomized Controlled Trials as Topic Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (7)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0 · commercial use OK